Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Work In Process: 2010-2020

Historic Work In Process for UNITED THERAPEUTICS (UTHR) over the last 9 years, with Mar 2020 value amounting to $28.1 million.

  • UNITED THERAPEUTICS's Work In Process rose 6.84% to $28.1 million in Q1 2020 from the same period last year, while for Mar 2020 it was $28.1 million, marking a year-over-year increase of 6.84%. This contributed to the annual value of $29.1 million for FY2019, which is 3.93% up from last year.
  • According to the latest figures from Q1 2020, UNITED THERAPEUTICS's Work In Process is $28.1 million, which was down 3.44% from $29.1 million recorded in Q4 2019.
  • UNITED THERAPEUTICS's 5-year Work In Process high stood at $29.8 million for Q3 2019, and its period low was $22.9 million during Q1 2017.
  • In the last 3 years, UNITED THERAPEUTICS's Work In Process had a median value of $28.0 million in 2018 and averaged $27.3 million.
  • In the last 5 years, UNITED THERAPEUTICS's Work In Process grew by 21.29% in 2016 and then declined by 13.33% in 2017.
  • UNITED THERAPEUTICS's Work In Process (Quarterly) stood at $24.9 million in 2016, then declined by 3.21% to $24.1 million in 2017, then climbed by 16.18% to $28.0 million in 2018, then climbed by 3.93% to $29.1 million in 2019, then increased by 6.84% to $28.1 million in 2020.
  • Its last three reported values are $28.1 million in Q1 2020, $29.1 million for Q4 2019, and $29.8 million during Q3 2019.